{"id":8838,"date":"2018-09-25T14:27:09","date_gmt":"2018-09-25T14:27:09","guid":{"rendered":"https:\/\/crigroup.com\/?post_type=case-study&p=8838"},"modified":"2022-03-30T08:40:04","modified_gmt":"2022-03-30T08:40:04","slug":"iso-37001-for-life-science-industry","status":"publish","type":"case-study","link":"https:\/\/crigroup.com\/ar\/case-study\/iso-37001-for-life-science-industry\/","title":{"rendered":"How can life sciences companies prevent bribery and corruption with compliance? Is ISO 37001 the answer?"},"content":{"rendered":"
ISO 37001 for the life science industry. Does ISO 37001 Anti-bribery Management Systems (ABMS) be able to eradicate unethical practices in the life sciences industry? Given the crucial role that healthcare plays in society, the impact of unethical and\/or illegal behaviour can be particularly harmful.<\/p>\n
CRI Group (parent brand of ABAC) has conducted an empirical review of international laws and conventions; professional association codes; and individual company Anti-Bribery and Anti-Corruption policies, as well as conducting in-depth interviews with ABAC and Life Sciences legal professionals, in order to validate the efficacy of existing measures, and to identify gaps in good practice and enforcement.<\/p>\n
Our analysis of six pharmaceutical companies (GlaxoSmithKline, Pfizer, Merck\/MSD, Novartis AG, AstraZeneca PLC, Johnson & Johnson) and their Anti-Bribery and Anti-Corruption violations found they all exhibited:<\/p>\n
All of these issues would, in theory, have been addressed by adherence to ISO 37001.<\/p>\n
Download your free ebook How can life sciences companies prevent bribery & corruption with compliance? Is ISO 37001 the answer?<\/a><\/strong><\/p>\n <\/p>\n <\/p>\n Who is CRI<\/span><\/strong>\u00ae<\/span>\u00a0Group?<\/span><\/strong><\/p>\n Based in London, CRI\u00ae Group works with companies across the Americas, Europe, Africa, Middle East and Asia-Pacific as a one-stop international\u00a0<\/span>Risk Management<\/span><\/a>,\u00a0<\/span>Employee Background Screening<\/span><\/a>,\u00a0<\/span>Business Intelligence<\/span><\/a>,\u00a0<\/span>TPRM<\/span><\/a>,\u00a0<\/span>Due Diligence<\/span><\/a>,\u00a0<\/span>Compliance Solutions<\/span><\/a>\u00a0and other professional\u00a0<\/span>Investigative Research<\/span><\/a>\u00a0solutions provider. We have the largest proprietary network of background-screening analysts and investigators across the Middle East and Asia. Our global presence ensures that no matter how international your operations are we have the network needed to provide you with all you need, wherever you happen to be. CRI\u00ae Group also holds\u00a0<\/span>BS 102000:2013<\/span><\/strong>\u00a0and\u00a0<\/span>BS 7858:2012 Certifications<\/span><\/strong>, is an HRO certified provider and partner with Oracle.<\/span><\/p>\n In 2016, CRI\u00ae Group launched\u00a0<\/span>Anti-Bribery Anti-Corruption (ABAC\u00ae) Center of Excellence<\/span><\/a>\u00a0\u2013 an independent certification body that provides education and certification services for individuals and organisations on a wide range of disciplines and ISO standards, including\u00a0<\/span>ISO 31000:2018 Risk Management- Guidelines<\/span><\/a>;\u00a0<\/span>ISO 37000:2021 Governance of Organisations<\/span><\/a>;\u00a0<\/span>ISO 37002:2021 Whistleblowing Management System<\/span><\/a>;\u00a0<\/span>ISO 37301:2021 (formerly ISO 19600) Compliance Management system (CMS)<\/span><\/a>;\u00a0<\/span>Anti-Money Laundering (AML)<\/span><\/a>; and\u00a0<\/span>ISO 37001:2016 Anti-Bribery Management Systems ABMS<\/span><\/a>. ABAC\u00ae offers a complete suite of solutions designed to help organisations mitigate the internal and external risks associated with operating in multi-jurisdiction and multi-cultural environments while assisting in developing frameworks for strategic compliance programs.\u00a0<\/span>Contact ABAC\u00ae for more<\/span><\/a>\u00a0on ISO Certification and training.<\/span><\/p>\n","protected":false},"featured_media":15828,"template":"","categories":[16,12,36],"tags":[],"class_list":["post-8838","case-study","type-case-study","status-publish","has-post-thumbnail","hentry","category-compliance-solution","category-due-diligence","category-pharmaceutical-healthcare"],"yoast_head":"\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\n\n\n\t\n<\/a><\/p>\n